Daclizumab Articles
Biogen jumps on strong MS drug data: Sanofi’s Lemtrada significant improvement on Rebif
24 October 2011
Biogen Idec ups offer 21% for Facet Biotech to $17.50 a share, which is again rejected by board
4 December 2009
Facet Biotech says Biogen Idec’s offer undervalues the firm
9 September 2009
Facet Biotech confirms hostile bid from Biogen Idec
7 September 2009
PDL shares plunge 32% as firm ends sale process
17 March 2008
Daclizumab impresses as MS therapy
22 October 2007
PDL BioPharma swings into 2nd-qtr profit
13 August 2007
Daclizumab impresses in Ph II MS study
19 March 2007
PDL's 4th-qtr net loss widens to $72.1M
5 March 2007
November a lackluster month for biotechnology stocks, says Burrill
18 December 2006
Stock Commentary - New York week to Nov 20, 2006
27 November 2006
Roche terminates PDL daclizumab accord
27 November 2006
Roche transfers daclizumab asthma rights back to PDL
25 September 2006
Biogen Idec and PDL form alliance
8 August 2005
Protein Design cuts losses in 3rd qtr
8 November 2004
Roche's Zenapax promising for asthma
27 September 2004
Stock Commentary - New York
24 May 2004
Ph II data for PDL's daclizumab in asthma
22 March 2004
Protein Design Labs buys Zenapax for $80M
6 October 2003
PDL is hit by asthma drug failure
19 May 2003
Roche's Zenapax cleared for use in children
15 July 2002
Another blow for PDL as Zamyl disappoints
27 May 2002
PDL yo-yos as Zenapax trial misses endpoint
1 April 2002
Enbrel also active in psoriasis, says study
4 March 2002
PDL drops on speculation on Zenapax data
25 February 2002
PDL to test Zenapax in asthma patients
28 November 2001
Ligand sells Marathon assets for $10 million
11 January 2000
Cash boost for Ligand as Elan raises stake
4 January 2000
Stock Commentary New York
28 October 1999
Roche's Zenapax approved by the European Commission
4 March 1999
Basiliximab Launched In The UK
8 December 1998
Roche's Rituxan/MabThera Warning In European Union
1 December 1998
Latest Wave Of US 1st Quarter Results
29 October 1998
EU Approval For Novartis' Simulect
16 October 1998
Roche Reports 32% Surge In 9 Months 1998 Sales
12 October 1998
First Half Sales At Roche Leap 41%, Boosted By BM
13 July 1998
Stock Commentary New York
18 June 1998
LeukoSite Lead Product May Be On Market By 2000
28 May 1998
Mixed Fortunes For US Companies In 1st Qtr
14 May 1998
US Biotech To Break Even By Start Of Millennium?
29 April 1998
Novartis Granted First Approval For Simulect
16 April 1998
Xenical Recommended For Approval By CPMP
16 April 1998
Zenapax Launched In Second Market
18 March 1998
Zenapax Approved In Switzerland
5 March 1998
Stock Commentary New York
19 February 1998
Roche's Zenapax Effective In Uveitis
19 February 1998
Round-Up Of Products Entering Clinical Trials
27 January 1998
Roche Sales Grew 18% In 1997; Pharma Up 15%
16 January 1998
Stock Commentary Europe
6 January 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Roche's Zenapax Gets First Approval For Transplants
17 December 1997
Celltech Reflects On Pipeline After Mixed Fortunes In '97
16 December 1997
Phase III Results With Novartis' Basiliximab
29 October 1997
Roche's Zenapax Gets Backing Of FDA Panel
23 October 1997
Roche Files With EMEA To Market Zenapax
10 September 1997
US Drug & Biotech Firms Post Quarterly Results
14 August 1997
PDL/Roche File For Zenapax In USA
19 June 1997
Roche And PDL Report Positive Data With Zenapax
19 May 1997
Six-Month Zenapax Data; Global Filing Set For 1H97
24 February 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
NEW YORK STOCK COMMENT
7 October 1996
Zenapax Results Boost PDL And Roche
7 October 1996
PDL Share Price Plummets As Trial Disappoints
2 September 1996
Brussels Probes Roche Austrian "Subsidy"
4 March 1996
Celltech Reduces Loss To L5.4 Million
18 December 1995
First Approval For Roche's Mycophenolate Mofetil
15 May 1995
Showing 1-84 of 84 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
